157 related articles for article (PubMed ID: 25043278)
21. Immunogenicity and Safety of a Sabin Strain-Based Inactivated Polio Vaccine: A Phase 3 Clinical Trial.
Hu Y; Wang J; Zeng G; Chu K; Jiang D; Zhu F; Ying Z; Chen L; Li C; Zhu F; Yin W
J Infect Dis; 2019 Oct; 220(10):1551-1557. PubMed ID: 30958543
[TBL] [Abstract][Full Text] [Related]
22. [The effect of aluminum adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine].
Wang F; Zhang M; Xie BF; Cao H; Tong SY; Wang JR; Yu XP; Tang Y; Yang JR; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):102-4. PubMed ID: 24044212
[TBL] [Abstract][Full Text] [Related]
23. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children.
Nakano T; Sumino S; Takanami Y; Mitsuya N; Nakatome K
Hum Vaccin Immunother; 2018; 14(12):2940-2949. PubMed ID: 30047808
[No Abstract] [Full Text] [Related]
24. Immune Serum From Sabin Inactivated Poliovirus Vaccine Immunization Neutralizes Multiple Individual Wild and Vaccine-Derived Polioviruses.
Sun M; Li C; Xu W; Liao G; Li R; Zhou J; Li Y; Cai W; Yan D; Che Y; Ying Z; Wang J; Yang H; Ma Y; Ma L; Ji G; Shi L; Jiang S; Li Q
Clin Infect Dis; 2017 May; 64(10):1317-1325. PubMed ID: 28419204
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.
Chen H; Gao Z; Bai S; Liu X; Han S; Xiao Y; Liu F; Yu Y; Sun H; Yang X
Vaccine; 2021 Apr; 39(17):2467-2474. PubMed ID: 33810904
[TBL] [Abstract][Full Text] [Related]
26. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
Ma Y; Qin M; Hu HQ; Ji G; Feng L; Gao N; Gu J; Xie BF; He JH; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun; 25(3):197-200. PubMed ID: 21977591
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity of fractional-dose of inactivated poliomyelitis vaccine made from Sabin strains delivered by intradermal vaccination in Wistar rats.
Ma Y; Ying Z; Li J; Gu Q; Wang X; Cai L; Shi L; Sun M
Biologicals; 2022 Jan; 75():3-11. PubMed ID: 35058137
[TBL] [Abstract][Full Text] [Related]
28. Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China.
Hu Y; Xu K; Han W; Chu K; Jiang D; Wang J; Tian X; Ying Z; Zhang Y; Li C; Zhu F
Open Forum Infect Dis; 2019 Oct; 6(10):ofz380. PubMed ID: 31660344
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: A randomized, controlled, open-label, phase IV clinical trial in China.
Yan S; Chen H; Zhang Z; Chang S; Xiao Y; Luo L; Zhang Z; Sun L; Chen X; Yang Y; Shi X; Guo Y; Sun Y; Li H; Li N; Han S; Ma M; Yang X
Vaccine; 2020 Sep; 38(40):6274-6279. PubMed ID: 32747216
[TBL] [Abstract][Full Text] [Related]
30. Effect of maternal antibody on the infant immune response to inactivated poliovirus vaccines made from Sabin strains.
Tang R; Chu K; Hu Y; Chen L; Zhang M; Liu S; Ma H; Wang J; Zhu F; Hu Y; Gao Q
Hum Vaccin Immunother; 2019; 15(5):1160-1166. PubMed ID: 30676838
[TBL] [Abstract][Full Text] [Related]
31. Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses.
Chu K; Han W; Jiang D; Jiang Z; Zhu T; Xu W; Hu Y; Zeng G
Expert Rev Vaccines; 2021 Jun; 20(6):761-767. PubMed ID: 33861679
[No Abstract] [Full Text] [Related]
32. Development of Thermostable Lyophilized Sabin Inactivated Poliovirus Vaccine.
Shin WJ; Hara D; Gbormittah F; Chang H; Chang BS; Jung JU
mBio; 2018 Nov; 9(6):. PubMed ID: 30482835
[TBL] [Abstract][Full Text] [Related]
33. Immune Persistence following Primary Immunization and the Immunogenicity and Safety of a Booster Dose of a Multidose Sabin Strain-Based Inactivated Polio Vaccine in Infants Aged 18 Months.
Feng G; Shao M; Wang J; Huang L; Tan J; Jiang Z; You W; Li Y; Yang Y; Li J; Wang Y
Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400106
[TBL] [Abstract][Full Text] [Related]
34. The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study.
Van Damme P; De Coster I; Bandyopadhyay AS; Revets H; Withanage K; De Smedt P; Suykens L; Oberste MS; Weldon WC; Costa-Clemens SA; Clemens R; Modlin J; Weiner AJ; Macadam AJ; Andino R; Kew OM; Konopka-Anstadt JL; Burns CC; Konz J; Wahid R; Gast C
Lancet; 2019 Jul; 394(10193):148-158. PubMed ID: 31174831
[TBL] [Abstract][Full Text] [Related]
35. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
36. Intranasal and sublingual delivery of inactivated polio vaccine.
Kraan H; Soema P; Amorij JP; Kersten G
Vaccine; 2017 May; 35(20):2647-2653. PubMed ID: 28400164
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial.
Bandyopadhyay AS; Gast C; Rivera L; Sáez-Llorens X; Oberste MS; Weldon WC; Modlin J; Clemens R; Costa Clemens SA; Jimeno J; Rüttimann R
Lancet Infect Dis; 2021 Apr; 21(4):559-568. PubMed ID: 33284114
[TBL] [Abstract][Full Text] [Related]
38. [Immunogenicity analysis of sequential inoculation of different strains of poliomyelitis vaccines in Shanghai].
Huang ZY; Sun XD; Liu MY; Li CS; Ren J; Hu JY; Yang JP; Liu JC; Li Z; Yang YY; Li YY; Lu J
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 May; 53(5):513-518. PubMed ID: 31091611
[No Abstract] [Full Text] [Related]
39. An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model.
Song S; Liu Z; Zhou J; Cai W; Yang H; Ma L; Gao J; Li W; Liao G
J Med Virol; 2019 Jan; 91(1):14-21. PubMed ID: 30168587
[TBL] [Abstract][Full Text] [Related]
40. The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines.
Jia S; Tang R; Li G; Hu Y; Liang Q
BMC Infect Dis; 2020 Aug; 20(1):641. PubMed ID: 32867698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
